Why people with prior SARS-CoV-2 infection still need to be vaccinated
Since vaccine shortage is expected to last at least for a few months, it may seem appealing to delay or avoid vaccinating those who have been naturally infected. But does…
Category: AstraZeneca
UK uses an untested strategy to rapidly but partially protect people at risk
With the virus running amok in the country and vaccines in short-supply, the U.K. is attempting an untested strategy of delaying the second dose of both AstraZeneca and Pfizer vaccine even in the absence of data from large trials. The intent is to rapidly but partially protect more individuals who are at risk.
COVID-19: Ethical challenges of vaccinating people with comorbidities
Unlike in other groups, national databases of people with comorbidities are not available. However, though not comprehensive, since 2010, State governments have been conducting population-based district level screening to detect…
Can COVID-19 vaccines with EUA be used at the population level?
Meanwhile, the Indian government has spelt out four high-risk groups — healthcare workers, frontline workers, those over 50 years of age and those aged below 50 years but with co-morbidities…
By putting the vaccine approval on hold for want of data, DCGI has underscored its priorities
The greatly reassuring decision to seek additional safety and immunogenicity data from the Pune-based Serum Institute of India and Hyderabad’s Bharat Biotech underlines the regulator’s priorities even for emergency use…
Transparency in COVID-19 vaccine trials vital to gain public trust
Unlike Pfizer, AstraZeneca, which is carrying out the phase-3 trials of the Oxford vaccine in four countries, is yet to secure a nod from any of the regulatory agencies despite…
Oxford vaccine shows 90% efficacy in Phase-3 trial
Two doses of the vaccine given in two different regimen showed different efficacies. In the case of the regimen (involving 2,741 participants) where a halved dose was used as a…
Pfizer’s COVID-19 vaccine shows promise, many unknowns remain
The results of the Phase-1 trial, announced in August, first through a press release and then through a preprint a week later, showed that the vaccine induced neutralising antibodies and…
